We looked at the association of RB1 mutation with response to immunotherapy in NSCLC by analyzing our data of 97 NSCLC patients treated with immunotherapy with second line nivolumab or first line pembrolizumab. Here, RB1 is linked to non-small cell lung carcinoma.